about
Bimatoprost-loaded ocular inserts as sustained release drug delivery systems for glaucoma treatment: in vitro and in vivo evaluationOcular Inserts for Sustained Release of the Angiotensin-Converting Enzyme 2 Activator, Diminazene Aceturate, to Treat Glaucoma in RatsCardiac safety of ophthalmic timolol.Safety evaluation of poly(lactic-co-glycolic acid)/poly(lactic-acid) microspheres through intravitreal injection in rabbits.Ocular delivery of macromoleculesLatrunculin B Reduces Intraocular Pressure in Human Ocular Hypertension and Primary Open-Angle Glaucoma.Promoting convergence: the Phi spiral in abduction of mouse corneal behaviors.A prototype antifungal contact lens.Diffusion of Antimicrobials Across Silicone Hydrogel Contact Lenses.A drug-eluting contact lensA cationic peptide, TAT-Cd°, inhibits herpes simplex virus type 1 ocular infection in vivo.Sustained reduction of intraocular pressure by supraciliary delivery of brimonidine-loaded poly(lactic acid) microspheres for the treatment of glaucomaContact lenses for drug delivery.Feasibility of lipid nanoparticles for ocular delivery of anti-inflammatory drugs.Emerging drugs for ocular hypertension.Metabolism of ophthalmic timolol: new aspects of an old drug.Novel drug delivery systems for glaucoma.Contact lenses for antifungal ocular drug delivery: a review.Clinicians' perspectives on the use of drug-eluting contact lenses for the treatment of glaucoma.Topical delivery of Avastin to the posterior segment of the eye in vivo using annexin A5-associated liposomes.Long Term Glaucoma Drug Delivery Using a Topically Retained Gel/Microsphere Eye DropRelease of Moxifloxacin from Contact Lenses Using an In Vitro Eye Model: Impact of Artificial Tear Fluid Composition and Mechanical Rubbing.In vivo performance of a drug-eluting contact lens to treat glaucoma for a month.A validated stability-indicating HPLC method for determination of brimonidine tartrate in BRI/PHEMA drug delivery systems.Design and evaluation of thermoreversible in situ gelling system of forskolin for the treatment of glaucoma.Principles of pharmacology in the eye.Ocular and systemic pharmacokinetics of lidocaine hydrochloride ophthalmic gel in rabbits after topical ocular administration.Preservative-Free Prostaglandin Analogs and Prostaglandin/Timolol Fixed Combinations in the Treatment of Glaucoma: Efficacy, Safety and Potential Advantages.Release of Moxifloxacin From Corneal Collagen Shields.Model for Porosity Changes Occurring during Ultrasound-Enhanced Transcorneal Drug Delivery.Microspheres as resistive elements in a check valve for low pressure and low flow rate conditions.A Rapid Extraction Method to Quantify Drug Uptake in Contact Lenses.Ocular drug delivery targeted by iontophoresis in the suprachoroidal space using a microneedle.Timolol maleate release from hyaluronic acid-containing model silicone hydrogel contact lens materials.In vitro drug release of natamycin from β-cyclodextrin and 2-hydroxypropyl-β-cyclodextrin-functionalized contact lens materials.The effect of silicone hydrogel contact lens composition on dexamethasone release.Extended Intravitreal Rabbit Eye Residence of Nanoparticles Conjugated With Cationic Arginine Peptides for Intraocular Drug Delivery: In Vivo Imaging
P2860
Q28538289-7497C0D1-0ACF-438E-B8AF-753835102408Q28546739-17E50034-8096-4F2B-8105-589B6D19E740Q33167596-05FB91EA-D5B0-4D6A-B1C7-4C88C85D094BQ33830339-2CFAC2EF-0B98-45BD-A517-FE260D6C9B54Q34079676-CB658BF0-7639-4701-B2A2-9663D790905BQ34181305-883E8BFE-7FAB-40C2-BE24-A4DFF7C09580Q35153150-5F3A3765-9AE2-464F-89FD-395B6FF5DCCBQ35221203-DF4D59C9-2AD3-41C2-ADDB-D944BA9486D8Q36005800-839D334C-824F-4046-84E5-AE6A0A82BB59Q36311472-7E61A6B4-73BC-410C-AC29-DA0BB441788DQ36591817-3938BFC1-9ED0-4D01-B96A-68CEF0A1606AQ36788792-577DAE0B-B3F2-45FC-84F4-31F9C13BCD87Q37479362-830D7792-6D02-474B-89B7-BD4AF733B062Q37769529-C98ACED3-0A2D-4EEB-8A5C-5F2069AB1B61Q37847182-BC2A5906-FE1F-437A-AAC7-C09C662DB15AQ37850837-B8288640-CEF6-400F-B004-9418697DBAAEQ37862989-74617361-F087-44C1-8A15-298E51ACC1C1Q38182719-320FC5D2-67FF-41BE-80C3-A203682A3310Q38270686-56AAA67E-5B5D-402F-B8C9-BB0BBEDF4B5BQ39018489-C5DAFBFD-09A7-45C1-B96A-FF108AB72C8CQ41448579-A053FD3C-3639-4F14-B45A-57B7196B255DQ42369732-3E8EDB6C-D620-4393-8489-392D5608833BQ42773028-52288C44-215E-4AEA-AE23-0DDC2C316208Q42943888-67F5A3C9-7A6E-45C9-97A8-5B5E008F2644Q43273081-C46BE6D2-6850-469E-BC10-ABE1C119A4FAQ45871474-C830AEEC-9F2A-425C-8A4A-2C453B714D20Q45929402-5D8B66B8-FA7A-4DB5-BD66-8EAEFA6EB034Q47381165-94D855A7-AE08-44FE-AF40-EAE09B07E14CQ49844534-336EF56B-471B-467D-B60B-E1B646A1A49EQ50778322-B047A616-A0F7-43B6-AA7F-84C18A9DA42AQ51537678-5319A059-B208-4FD1-A777-C628DE4FD99BQ52620262-CF7DD0A6-2F5E-4B49-8445-0C20F9ACB472Q52673868-3CBD83AA-347F-4AAE-985E-AD78988BFAB3Q53259773-3F8D3BB7-A7A5-4618-B120-27B06980B781Q53444182-70196079-131C-422A-9816-520B468DCA80Q53616759-E9B5560F-0607-4991-8CF7-26FC97F5F081Q58806008-F893B387-93A5-46BE-A330-9BFB704F8C02
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on March 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Barriers to glaucoma drug delivery.
@en
Barriers to glaucoma drug delivery.
@nl
type
label
Barriers to glaucoma drug delivery.
@en
Barriers to glaucoma drug delivery.
@nl
prefLabel
Barriers to glaucoma drug delivery.
@en
Barriers to glaucoma drug delivery.
@nl
P1433
P1476
Barriers to glaucoma drug delivery.
@en
P2093
Henry F Edelhauser
P304
P356
10.1097/IJG.0B013E31814B990D
P50
P577
2008-03-01T00:00:00Z